Photo of Amir T. Fathi,  MD

Amir T. Fathi, MD

Harvard Medical School

Harvard Medical School
Phone: (617) 724-1124
Fax: (617) 724-1126


afathi@partners.org

Amir T. Fathi, MD

Harvard Medical School

EDUCATIONAL TITLES

  • Assistant Professor, Medicine, Harvard Medical School

DF/HCC PROGRAM AFFILIATION

Research Abstract

Acute myeloid leukemia is associated with a poor prognosis, and standard therapeutic approaches have not significantly changed in the last few decades. There is a dire need for novel therapies to improve clinical outcomes. My research interest focuses on the development and clinical translation of promising therapeutics for patients with acute leukemias. I lead multiple clinical trials at the Dana Farber Harvard Cancer Center for such patients, and have a specific interest in IDH-inhibition, aurora kinase inhibition, FLT3 inhibition, and antibody-drug conjugates as novel therapeutic approaches for patients with acute leukemias.

Publications

Powered by Harvard Catalyst
  • Hobbs AM, Jalbut MM, Neuberg DS, Fathi AT. A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database. Leuk Lymphoma 2015. PubMed
  • Fathi AT, Wander SA, Faramand R, Emadi A. Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia. Semin Hematol 2015; 52:165-71. PubMed
  • Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Klimek V, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Scott B, Shami PJ, Stein BL, Westervelt P, Wheeler B, Shead DA, Smith C. Myelodysplastic syndromes, version 2.2015. J Natl Compr Canc Netw 2015; 13:261-72. PubMed
  • Jalbut MM, Sohani AR, Dal Cin P, Hasserjian RP, Moran JA, Brunner AM, Fathi AT. Acute myeloid leukemia in a patient with constitutional 47,XXY karyotype. Leuk Res Rep 2015; 4:28-30. PubMed
  • O'Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, Curtin P, DeAngelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Jagasia M, Kropf P, Moore JO, Pallera A, Reddy VV, Shah NP, Smith BD, Snyder DS, Wetzler M, Gregory K, Sundar H. Chronic myelogenous leukemia, version 1.2015. J Natl Compr Canc Netw 2014; 12:1590-610. PubMed
  • Movassaghian M, Brunner AM, Blonquist TM, Sadrzadeh H, Bhatia A, Perry AM, Attar EC, Amrein PC, Ballen KK, Neuberg DS, Fathi AT. Presentation and outcomes among patients with isolated myeloid sarcoma: a Surveillance, Epidemiology, and End Results database analysis. Leuk Lymphoma 2014. PubMed
  • Chen YB, Li S, Lane AA, Connolly C, Del Rio C, Valles B, Curtis M, Ballen K, Cutler C, Dey BR, El-Jawahri A, Fathi AT, Ho VT, Joyce A, McAfee S, Rudek M, Rajkhowa T, Verselis S, Antin JH, Spitzer TR, Levis M, Soiffer R. Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia. Biol Blood Marrow Transplant 2014. PubMed
  • Movassaghian M, Sohani AR, McAfee SL, Perry AM, Dal Cin P, McLaughlin C, Fathi AT. Chromosome 17p deletion in a case of T-cell acute lymphoblastic lymphoma. Am J Hematol 2014. PubMed
  • Fathi AT, Lin WM, Durazzo T, Piris A, Sadrzadeh H, Bernardo L, Borger DR, McAfee SL, Kroshinsky D, Chen YB. Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia. J Clin Oncol 2014. PubMed
  • Brunner AM, Blonquist TM, Sadrzadeh H, Perry AM, Attar EC, Amrein PC, Ballen KK, Chen YB, Neuberg DS, Fathi AT. Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: A SEER database analysis. Leuk Res 2014; 38:773-80. PubMed
  • Wander SA, Levis MJ, Fathi AT. The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. Ther Adv Hematol 2014; 5:65-77. PubMed
  • Fathi AT, Sadrzadeh H, Comander AH, Higgins MJ, Bardia A, Perry A, Burke M, Silver R, Matulis CR, Straley KS, Yen KE, Agresta S, Kim H, Schenkein DP, Borger DR. Isocitrate Dehydrogenase 1 (IDH1) Mutation in Breast Adenocarcinoma Is Associated With Elevated Levels of Serum and Urine 2-Hydroxyglutarate. Oncologist 2014. PubMed
  • Emadi A, Jun SA, Tsukamoto T, Fathi AT, Minden MD, Dang CV. Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Exp Hematol 2014; 42:247-51. PubMed
  • Fathi AT, Chen YB. Treatment of Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. Curr Hematol Malig Rep 2014. PubMed
  • Fathi AT, Chen YB. CD30: a new target for ALL? Leuk Lymphoma 2014; 55:478-9. PubMed
  • Akbay EA, Moslehi J, Christensen CL, Saha S, Tchaicha JH, Ramkissoon SH, Stewart KM, Carretero J, Kikuchi E, Zhang H, Cohoon TJ, Murray S, Liu W, Uno K, Fisch S, Jones K, Gurumurthy S, Gliser C, Choe S, Keenan M, Son J, Stanley I, Losman JA, Padera R, Bronson RT, Asara JM, Abdel-Wahab O, Amrein PC, Fathi AT, Danial NN, Kimmelman AC, Kung AL, Ligon KL, Yen KE, Kaelin WG, Bardeesy N, Wong KK. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev 2014; 28:479-90. PubMed
  • Fathi AT, Dec GW, Richter JM, Chen YB, Schwartzenberg SS, Holmvang G, Hasserjian RP. Case records of the Massachusetts General Hospital. Case 7-2014. A 27-year-old man with diarrhea, fatigue, and eosinophilia. N Engl J Med 2014; 370:861-72. PubMed
  • Graubert TA, Brunner AM, Fathi AT. New Molecular Abnormalities and Clonal Architecture in AML: From Reciprocal Translocations to Whole-Genome Sequencing. Am Soc Clin Oncol Educ Book 2014; 34:e334-40. PubMed
  • Fathi AT. Emergence of crenolanib for FLT3-mutant AML. Blood 2013; 122:3547-8. PubMed
  • O'Brien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, DeAngelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Jagasia M, Kropf P, Moore JO, Pallera A, Pinilla-Ibarz J, Reddy VV, Shah NP, Smith BD, Snyder DS, Wetzler M, Gregory K, Sundar H. Chronic Myelogenous Leukemia, Version 1.2014. J Natl Compr Canc Netw 2013; 11:1327-40. PubMed
  • Peloquin GL, Chen YB, Fathi AT. The evolving landscape in the therapy of acute myeloid leukemia. Protein Cell 2013; 4:735-46. PubMed
  • Attar EC, Amrein PC, Fraser JW, Fathi AT, McAfee S, Wadleigh M, Deangelo DJ, Steensma DP, Stone RM, Foster J, Neuberg D, Ballen KK. Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leuk Res 2013; 37:1016-20. PubMed
  • Fathi AT, Le L, Hasserjian RP, Sadrzadeh H, Levis M, Chen YB. FLT3 inhibitor-induced neutrophilic dermatosis. Blood 2013; 122:239-42. PubMed
  • Zhang Y, Wang J, Wheat J, Chen X, Jin S, Sadrzadeh H, Fathi AT, Peterson RT, Kung AL, Sweetser DA, Yeh JR. AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/硫-catenin signaling pathway. Blood 2013; 121:4906-16. PubMed
  • Sadrzadeh H, Kerr DA, Cin PD, Lindeman NI, Hasserjian RP, Fathi AT. A unique PML-RAR留 rearrangement involving chromosomes 11, 15, and 17 in a patient with acute promyelocytic leukemia. Exp Hematol 2013. PubMed
  • Brunner AM, Sadrzadeh H, Feng Y, Drapkin BJ, Ballen KK, Attar EC, Amrein PC, McAfee SL, Chen YB, Scd DS, Fathi AT. Association between baseline body mass index (BMI) and overall survival among patients over age 60 with acute myeloid leukemia (AML). Am J Hematol 2013. PubMed
  • Brunner AM, Campigotto F, Sadrzadeh H, Drapkin BJ, Chen YB, Neuberg DS, Fathi AT. Trends in all-cause mortality among patients with chronic myeloid leukemia: A Surveillance, Epidemiology, and End Results database analysis. Cancer 2013. PubMed
  • Sadrzadeh H, Hasserjian R, Fathi AT. Pure erythroid leukemia evolving from a therapy-related myelodysplastic syndrome secondary to treatment for chronic lymphocytic leukemia. Am J Hematol 2013; 88:240-1. PubMed
  • Sadrzadeh H, Huck AE, Chen YB, Hasserjian RP, Fathi AT. Philadelphia chromosome positive B-cell lymphoblastic lymphoma isolated to bone. Leuk Lymphoma 2013. PubMed
  • Courville EL, Wu Y, Kourda J, Roth CG, Brockmann J, Muzikansky A, Fathi AT, de Leval L, Orazi A, Hasserjian RP. Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia. Mod Pathol 2013. PubMed
  • Sadrzadeh H, Abtahi SM, Fathi AT. Infectious pathogens and hematologic malignancy. Discov Med 2012; 14:421-33. PubMed
  • Fathi AT, Sadrzadeh H, Borger DR, Ballen KK, Amrein PC, Attar EC, Foster J, Burke M, Lopez HU, Matulis CR, Edmonds KM, Iafrate AJ, Straley KS, Yen KE, Agresta S, Schenkein DP, Hill C, Emadi A, Neuberg DS, Stone RM, Chen YB. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood 2012. PubMed
  • Fathi AT, Preffer FI, Sadrzadeh H, Ballen KK, Amrein PC, Attar EC, McAfee SL, Dillon L, Chen YB, Hasserjian RP. CD30 expression in acute myeloid leukemia is associated with FLT3-internal tandem duplication mutation and leukocytosis. Leuk Lymphoma 2012. PubMed
  • Fathi AT, Chen YB, Carter BW, Ryan RJ. Case records of the Massachusetts General Hospital. Case 24-2012. A 38-year-old man with abdominal pain and altered mental status. N Engl J Med 2012; 367:552-63. PubMed
  • Fathi A, Levis M. FLT3 inhibitors: a story of the old and the new. Curr Opin Hematol 2011; 18:71-6. PubMed
  • Fathi AT, Grant S, Karp JE. Exploiting cellular pathways to develop new treatment strategies for AML. Cancer Treat Rev 2010; 36:142-50. PubMed
  • Fathi AT, Karp JE. New agents in acute myeloid leukemia: beyond cytarabine and anthracyclines. Curr Oncol Rep 2009; 11:346-52. PubMed
Hide